Prof. Dr Mark Dawson
Head of Roche Pharma Research and Early Development (pRED) (Member of the enlarged CEC since 2026)
:quality(90)/)
About Roche
Our leadership team
Personal Data
Nationality
Australia, United Kingdom
Year of Birth
1974
Education
1993–1999
University of Melbourne, Bachelor of Medicine, Bachelor of Surgery (MBBS)
1999
University of Melbourne, Bachelor of Medical Science (BMedSci.)
2003–2007
Fellowship of Royal Australasian College of Physicians (FRACP)
2003–2007
Fellowship of Royal College of Pathologists of Australasia (FRCPA)
2007–2009
University of Cambridge, Doctorate in Molecular Biology (PhD)
Professional experience
2000–2003
St. Vincent’s Hospital Melbourne, Internship & Medical Residency
2004–2006
Alfred Hospital Melbourne, Specialist Training in Clinical Haematology & Haematopathology
2007–2014
University of Cambridge, Consultant Haematologist, Addenbrooke’s Hospital
2009–2014
University of Cambridge, Cambridge Institute for Medical Research and The Gurdon Institute, Wellcome Beit Fellow
2014–2026
Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Consultant Haematologist
Since 2016
University of Melbourne, Sir Peter MacCallum Department of Oncology and Centre for Cancer Research, Professor
2016–2018
Peter MacCallum Cancer Centre, Program Head Translation Haematology
2018–2025
Peter MacCallum Cancer Centre, Program Head Cancer Biology & Therapeutics
2019–2026
Peter MacCallum Cancer Centre, Associate Director of Research
2019–2026
Peter MacCallum Cancer Centre, Research Executive
Since 2026
Roche, Basel, Head of Roche Pharma Research and Early Development (pRED)
Present external mandates
in listed companies
–
in unlisted companies
–
Other activities / non-profit activities / memberships
Academic Appointments
2011–2014
Research Fellow, St John’s College, University of Cambridge
2014–2017
VESKI Innovation Fellow
2014–2019
Senior Fellow, Leukaemia Foundation of Australia
2017–2023
International Scholar, Howard Hughes Medical Institute
2019–2024
Sir Edward Dunlop Fellow, Cancer Council of Victoria
2019–2026
Dame Kate Campbell Fellow, University of Melbourne
Since 2019
Investigator, National Health & Medical Research Council
Scientific Advisory Boards
2015–2020
Cancer Therapeutics CRC
2017–2025
Cambridge Epigenetix / BioModal
2017–2025
Storm Therapeutics
Since 2022
James P. Allison Institute, MD Anderson Cancer Center
Since 2025
Paris Leukemia Institute
Professional Memberships
Since 2017
Australian Academy of Health and Medical Sciences
Since 2021
Australian Academy of Science
Since 2021
European Molecular Biology Organisation
Awards / Honors
2006
General Sir John Monash Fellowship
2006
Cambridge Commonwealth Trust Fellowship
2009
Wellcome Beit Prize Fellowship
2017
Metcalf Prize for Stem Cell Research, National Stem Cell Foundation of Australia
2020
Prime Minister’s Prize for Science (Life Scientist of the Year)
2020
McCulloch & Till Award from the International Society of Experimental Hematology,
2021
Jacques Miller Medal from The Australian Academy of Science
2023
The Paul Marks Prize for Cancer Research from Memorial Sloan Kettering Cancer Centre
2025
William Dameshek Prize, American Society of Hematology (ASH)